Home › Trial NCT02827201
FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
- Trial IDNCT02827201
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorFederation Francophone de Cancerologie Digestive
- Enrollment127
- Start date2015-11
- ConditionsMetastatic Pancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.